Clinical Trial Update: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Prifetrastat (PF-07248144) in combination with Fulvestrant for HR+/HER2- breast cancer. The study is planned to extend to meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma

Drugs mentioned

• Fulvestrant (fulvestrant)
• Prifetrastat (PF-07248144)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic (Stage IV) Melanoma | Phase 2 | Status: NOT_YET_RECRUITING